ReviewCureus2026
Molecular Pathology in Modern Medicine: A Review of Genomic, Proteomic, and Epigenetic Insights Into Disease Mechanisms.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Retraction · 2026-03-27Euphemisms for Plagiarism · Plagiarism of/in Article ·
- Retracted
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Molecular pathology has become a central discipline in modern medicine by enabling the systematic interrogation of genomic, proteomic, and epigenetic alterations that underlie human disease mechanisms. This review synthesises how genomic variants, proteomic dysregulation, and epigenetic alterations interact to drive disease initiation, progression, and phenotypic heterogeneity. Key molecular pathology platforms, including whole-genome sequencing, mass spectrometry-based proteomics, and epigenetic profiling, are examined as tools for elucidating disease mechanisms in modern medicine. Computational strategies, including multimodal data harmonisation, causal and network models, and interpretable artificial intelligence (AI), enable mechanism-anchored patient endotyping and therapy selection; clinical decision support and pharmacogenomics (PGx) translate molecular evidence into action. Considerations influencing the implementation of integrative molecular pathology include pre-analytical handling, platform-specific characteristics, data harmonisation, economic feasibility, model interpretability, reproducibility, and the extent of prospective clinical validation and reimbursement pathways. Recommended priorities include standards for pipeline validation, longitudinal and minimally invasive monitoring, deployable multimodal AI with uncertainty estimates, and equitable data governance. Molecular pathology reframes diagnostics in modern medicine by shifting from isolated markers toward a mechanistic understanding of disease biology across oncology and complex disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.